SCHEMBL17670467

SCHEMBL17670467

Cc1cc(C(=O)O)cc(CNCc2nccn2CCC(C)C)n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 2/20 0.34
▸ ADORA1 P30542 2/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ RXFP1 Q9HBX9 1/20 0.32
▸ KDM5B Q9UGL1 2/20 0.32
▸ ADORA3 P0DMS8 1/20 0.31
▸ ADORA2B P29275 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ FPR2 P25090 2/20 0.31
▸ ADRA2C P18825 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ PIK3CA P42336 1/20 0.30
▸ PIK3CG P48736 1/20 0.30
▸ KDM6B O15054 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17549907 0.89 BRD4 (0.34) ADORA2AADORA1SMN1; SMN2MEN1KMT2A
SCHEMBL17670496 0.84 ALDH1A1 (0.40) SMN1; SMN2MEN1KMT2ANPSR1TDP1
SCHEMBL17549930 0.82 MEN1 (0.32) MEN1KMT2ANPSR1TDP1L3MBTL1
SCHEMBL17544777 0.82 HSP90AA1 (0.36) ADORA2AADORA1MEN1KMT2ANPSR1
SCHEMBL17683749 0.82 YTHDC1 (0.34) ADORA2AADORA1KMT2A
SCHEMBL17670498 0.80 HSP90B1 (0.40) MEN1KMT2AALDH1A1
SCHEMBL19522722 0.79 KDM4C (0.42) MEN1KMT2A
SCHEMBL17670471 0.79 P2RY14 (0.38) SMN1; SMN2MEN1KMT2ARAB9A
SCHEMBL17549883 0.79 HSP90AA1 (0.44) KDM5BRAB9ALMNAPIK3CAPIK3CG
SCHEMBL17670343 0.78 L3MBTL1 (0.41) SMN1; SMN2L3MBTL1RXFP1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9802941-B2 Compounds and methods for inhibiting histone demethylases GILEAD SCIENCES, INC. (US) 2017-10-31 — — US disclosed
US-9802941-B2 Compounds and methods for inhibiting histone demethylases GILEAD SCIENCES, INC. (US) 2017-10-31 — — US disclosed
US-20160102096-A1 COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES EPITHERAPEUTICS APS 2016-04-14 — — US disclosed
US-20160102096-A1 COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES EPITHERAPEUTICS APS 2016-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102096-A1 COMPOUNDS AND METHODS FOR INHIBITING HISTONE DEMETHYLASES PHF8, KDM3A, PHF2 ADORA2A 3462/4885ADORA1 3871/4885SMN1; SMN2 3889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback